Acquisitions Help Strides Back Into Black
This article was originally published in PharmAsia News
Executive Summary
Indian drug maker Strides Arcolab, which is aiming to build a global business-to-customer operation driven by its own product pipeline, swung to a net profit in the second financial quarter from a year ago, propelled by strong across-the-board sales momentum following a string of acquisitions. It is now looking at "very good growth from its combined assets."